2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

5994 Impact of early vs. delayed gastrointestinal infections on graft versus host disease (GVHD) severity and mortality in hematopoietic stem cell transplant (HSCT) recipients

Krishna Doshi, MD, Nandhini Iyer, MD, MBBS2, Safa S Afridi, MD3, Sergio Hernandez Llamas, MD4, Adolfo Diaz Duque, MD, MSc5
1 University of Texas Health San Antonio, San Antonio, United States
2 Loyola University Health System-MacNeal Hospital, Berwyn, United States
3 SUNY Upstate Medical University, Syracuse, United States
4 University of Texas Health San Antonio, San Antonio, United States
5 University of Texas Health San Antonio, San Antonio, United States

Introduction:Gastrointestinal (GI) infections are common complications following hematopoietic stem cell transplantation (HSCT) and may contribute to adverse post-transplant outcomes, including graft-versus-host disease (GVHD). The GI tract is a primary target of GVHD, and epithelial injury can promote microbial translocation, systemic immune activation, and cytokine-mediated inflammation that may exacerbate disease severity. Although prior studies have demonstrated an association between infections and GVHD, few have specifically evaluated how the timing of GI infections influences GVHD risk and clinical outcomes. We examined the impact of early (1–30 days) versus delayed (31–100 days) GI infections after HSCT on GVHD incidence, hospitalization rates, and 180-day survival in a large multicenter retrospective cohort.

Methods: We performed a retrospective propensity score-matched cohort study using the TriNetX US Collaborative Network. Adult HSCT recipients (≥18 years; ICD-10 Z94.84) who developed a GI infection within 100 days following transplantation were identified using ICD-10 codes A04, A06, A08, A09, and K52. Patients were categorized into Early (1–30 days) and Delayed (31–100 days) GI infection cohorts. Patients with a history of solid organ transplantation (ICD-10 Z94.0–Z94.83) were excluded. Cohorts were matched 1:1 using propensity scores to balance age, sex, race, and transplant status.Outcomes included acute GVHD (D89.810), chronic GVHD (D89.811), hospital admissions, 180-day survival, and GVHD recurrence. GVHD recurrence was assessed using the cumulative number of documented acute and chronic GVHD diagnostic encounters recorded during the follow-up period ("number of instances" analysis in TriNetX).Risk ratios, odds ratios, and number-of-instances analyses were used to compare outcomes between cohorts. Kaplan-Meier survival analysis and Cox proportional hazards modeling were performed to evaluate survival and estimate hazard ratios (HR) with 95% confidence intervals.

Results- After 1:1 propensity score matching, 10,142 patients were included in each cohort. Patients with early GI infections (1–30 days post-HSCT) demonstrated significantly higher incidences of both acute GVHD (ICD-10: D89.810) and chronic GVHD (ICD-10: D89.811) compared with those with delayed infections (31–100 days post-HSCT). Hospitalization rates were substantially increased in the early infection cohort (30.1% vs. 19.8%), corresponding to a risk ratio (RR) of 1.53 and an odds ratio (OR) of 1.75 (p<0.001). Kaplan-Meier analysis demonstrated inferior 180-day survival among patients with early GI infections (68.96% vs. 79.42%). Early infection was associated with significantly increased mortality risk (HR 1.656, 95% CI 1.423–1.928; p<0.001). Additionally, The cumulative number of documented GVHD-related encounters was greater in the early GI cohort, suggesting a higher burden of GVHD and potentially more persistent disease activity. Overall, a temporal relationship was observed with earlier GI infections associated with progressively worse GVHD-related and survival outcomes.

Conclusion: In this large multicenter propensity-matched cohort, early gastrointestinal infections occurring within 30 days of HSCT were associated with significantly higher rates of acute and chronic GVHD, increased hospitalizations, and inferior 180-day survival compared with infections occurring later in the post-transplant course. These findings support the hypothesis that infectious injury during early immune reconstitution may amplify alloimmune activation and contribute to subsequent GVHD severity and adverse clinical outcomes. Timely surveillance and gut-protective interventions in the early post-transplant period may help mitigate the risk of GVHD and improve outcomes. Further studies evaluating gut microbiome and barrier preservation may be beneficial.

Krishna Doshi, MD: No relevant conflicts of interest to declare.